@article{LimayeTodiShroffetal.2017,
  author    = {Dnyanesh Limaye and Krishna Todi and Jay Shroff and Ashutosh Ramaswamy and Priyanka Kulkarni and Vaidehi Limaye and Gerhard Fortwengel},
  title     = {Cost-effectiveness study of antidiabetic drugs in type 2 diabetes mellitus patients from Mumbai, India},
  series   = {International Journal of Community Medicine and Public Health},
  volume    = {4},
  number    = {9},
  doi       = {10.25968/opus-1904},
  url       = {http://nbn-resolving.de/urn:nbn:de:bsz:960-opus4-19049},
  pages     = {3180 -- 3185},
  year      = {2017},
  abstract  = {Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US\$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India. Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5). Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness.},
  language  = {en}
}